Literature DB >> 2857146

Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease.

R A van Hogezand, P A van Hees, B Zwanenburg, J M van Rossum, J H van Tongeren.   

Abstract

The disposition of disodium azodisalicylate and salicylazosulfapyridine was studied in 6 healthy volunteers. After a single oral dose (1.0 g disodium azodisalicylate; 2.3 g salicylazosulfapyridine) maximum serum concentrations of the intact compound ranged between 1.4 and 6.8 mumol/L and 32 and 114 mumol/L, respectively. Mean residence time and serum half-life of disodium azodisalicylate were considerably longer than those of salicylazosulfapyridine, probably because of a higher apparent volume of distribution. Both compounds were largely split by colonic bacteria and comparable amounts of the active moiety, (acetyl-)5-aminosalicylic acid, were recovered in feces. During long-term ingestion of disodium azodisalicylate (1.0 g/day) it took 6-19 days to reach a steady state. Serum concentrations of disodium azodisalicylate at steady state were low: 2.2-8.4 mumol/L. The serum half-life was 6-10 days. It is concluded that the disposition of disodium azodisalicylate is similar, in important respects, to that of salicylazosulfapyridine. Disodium azodisalicylate, therefore, deserves therapeutic trial.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857146     DOI: 10.1016/0016-5085(85)90142-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions.

Authors:  R A van Hogezand; H M Kennis; A van Schaik; J P Koopman; P A van Hees; J H van Tongeren
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Secretory effect of azodisalicylate (azodisal sodium) on the short circuited mucosa of the rat ileum in vitro.

Authors:  K J Goerg; R Wanitschke; P H Diehl; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

4.  Absorption of 5-aminosalicylic acid from colon and rectum.

Authors:  S Bondesen; J B Schou; V Pedersen; Z Rafiolsadat; S H Hansen; E F Hvidberg
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

Review 5.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

6.  Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects.

Authors:  A H Raimundo; D H Patil; P G Frost; D B Silk
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

7.  Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.

Authors:  K Lauritsen; L Staerk Laursen; K Bukhave; J Rask-Madsen
Journal:  Gut       Date:  1988-07       Impact factor: 23.059

8.  Stability of disodium azodisalicylate (olsalazine) and metabolites in urine and faeces stored at different temperatures.

Authors:  R A van Hogezand; A van Schaik; P A van Hees; J H van Tongeren
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

9.  Biliary excretion of olsalazine sodium in humans.

Authors:  M Ryde; S Gustavsson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

10.  The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food.

Authors:  E M Ryde; N O Ahnfelt
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.